Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease

Takaki, Yugo; Mizuochi, Tatsuki; Eda, Keisuke; Ishihara, Jun; Yamashita, Yushiro

doi:10.1111/ped.13892

Cited by 8 publications

(7 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although endoscopy can never be completely replaced, fecal and blood biomarkers can provide noninvasive, repeatable, and cost-effective assays for disease monitoring in IBD. 28 , 29 Compared with blood indicators, fecal biomarkers such as FC that directly contact inflamed intestines are more desirable for clinical routines. This research provided the first evidence that OSM was a novel fecal biomarker, along with FC, and their combination was more beneficial for IBD management in specific clinical situations.…”

Section: Discussionmentioning

confidence: 99%

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

Cao¹,

Dai²,

Zhang³

et al. 2021

JIR

View full text Add to dashboard Cite

Background Fecal biomarkers have emerged as one of the most useful tools for clinical management of inflammatory bowel disease (IBD). Oncostatin M (OSM), like fecal calprotectin (FC), is highly expressed in the inflamed intestinal mucosa which may have potential usefulness. We aimed to evaluate the additional utility of these two fecal biomarkers for IBD diagnosis, activity, and prediction of infliximab response over FC alone. Methods In group 1, 236 IBD patients (145 Crohn’s disease, 91 ulcerative colitis), 50 disease controls, and 32 healthy controls were recruited for IBD diagnosis and activity. In group 2, baseline stool samples were collected from 62 patients to predict infliximab response at week 28 and 52. The performance of fecal biomarkers for IBD management was assessed by the area under the receiver operating characteristic curve (AUC). Results Fecal OSM and FC levels were increased in IBD patients and were positively correlated with clinical and endoscopic activity. Their combination showed a better ability for disease diagnosis (AUC = 0.93) and slightly improved the capability to identify mucosal healing (AUC = 0.923). Baseline OSM and FC levels were elevated in non-responders at week 28 and 52. The AUCs of OSM, FC, and their combination to predict therapeutic response were 0.763, 0.834, and 0.859 at week 28, 0.638, 0.661, and 0.704 at week 52, respectively. Combined use of fecal and blood biomarkers improved predictive accuracy with an AUC of 0.919 at week 28 and 0.887 at week 52. Conclusion In addition to FC, OSM is a novel fecal biomarker, and their combination is more beneficial for disease diagnosis and prediction of infliximab response but not for disease activity in IBD patients. Further larger-scale studies are required to confirm our findings.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

Cao¹,

Dai²,

Zhang³

et al. 2021

JIR

View full text Add to dashboard Cite

show abstract

“…However, the trends of some parameters in pediatric patients with IBD have been reported to differ between UC and CD at initial diagnosis. Patients with CD have lower albumin and hemoglobin levels and higher erythrocyte sedimentation rates, C-reactive protein levels, and platelet counts than those with UC [ 36 37 38 39 ]. In our study, laboratory parameters were compared between the cCD and rUC groups.…”

Section: Discussionmentioning

confidence: 99%

“…This result is similar to the findings of a previous study, which reported that hypoalbuminemia could be a predictor of the diagnostic change from IBDU to CD [ 12 ]. Other studies have emphasized that differences in laboratory parameters could be affected by the distribution and severity of disease [ 37 39 ]. Mack et al [ 38 ] have reported that patients with colon-only CD are more likely to show normal laboratory parameters than those with CD involving the small intestine or the upper gastrointestinal tract.…”

Section: Discussionmentioning

confidence: 99%

Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience

Ito

Takeuchi

Kyodo

et al. 2021

Pediatr Gastroenterol Hepatol Nutr

View full text Add to dashboard Cite

Purpose A change in diagnosis from ulcerative colitis (UC) to Crohn's disease (CD) has been reported in pediatric inflammatory bowel disease; however, only a few clinical characteristics and predictors of this diagnostic change have been reported. We aimed to describe the clinical characteristics of patients with UC who underwent a change in diagnosis to CD and identify variables associated with the change. Methods The medical records of pediatric patients with UC who were followed up at the National Center for Child Health and Development between 2006 and 2019 were retrospectively reviewed. Clinical data on disease phenotype, laboratory parameters, endoscopic findings, and treatment of patients whose diagnosis changed to CD (cCD) were compared to those of patients whose diagnosis remained UC (rUC). Results Among the 111 patients initially diagnosed with UC, 11 (9.9%) patients were subsequently diagnosed with CD during follow-up. There was no significant difference between the cCD and rUC groups in terms of sex, age at initial diagnosis, and the extent and severity of disease at initial diagnosis. Albumin and hemoglobin levels were significantly lower in the cCD group than in the rUC group. The proportion of patients who required biologics was significantly higher in the cCD group than in the rUC group ( p <0.05). Conclusion Approximately 10% children initially diagnosed with UC were subsequently diagnosed with CD. Hypoalbuminemia and anemia at initial diagnosis and use of biologics could be predictors of this diagnostic change.

show abstract

“…Збільшення кількості лімфоцитів >37%, моноцитів >11%, еозинофілів >5% документована у пацієнтів всіх груп, але достовірних відмінностей їх показників знайдено не було (p>0,05). Отримані нами результати співпадають з даними літератури [24,29].…”

unclassified

“…Наведене дозволяє зробити висновок про те, що клінічні симптоми тісно пов'язані з такими показниками гемограми як гемоглобін, лейкоцити, тромбоцити, ШОЕ, а також концентрація фекального кальпротектину, γ-глобулінів, показника АГ-коефіцієнту, які можуть бути використані як критерії перебігу захворювання та моніторингу базової терапії пацієнтів. Наші дані збігаються з результатами щодо прогностичної значимості комбінації лейкоцитів, тромбоцитів, ШОЕ для виявлення тяжкості ВК [23,29].…”

unclassified

Clinical Forms of Ulcerative Colitis and Their Features in Children

Денисова¹,

Букулова²

2020

RS Global - Science Review

View full text Add to dashboard Cite

This article presents frequency of occurrence of clinical forms of the disease depending on the localization and activity of the inflammatory process, their age and gender differences, risk factors and disease triggers, based on a retrospective analysis of 116 cases of children with ulcerative colitis at the age of 4-18 years. Comparative clinical, laboratory and endoscopic characteristics of total, segmental and distal colitis have been also analyzed. It was found that clinical activity of total colitis is characterized by more severe course of the disease, accompanied with systemic and local extraintestinal manifestations (OR = 4,504±0,506, p<0.05), more pronounced changes in hemo- and proteinogram parameters (p<0.05). Endoscopic criteria for differences in the clinical forms of ulcerative colitis are the presence of ulcers (OR = 9,667±0,645, p <0,05), erosions (OR = 3,569±0,429, p<0,05), contact bleeding (OR = 4,364± ,444, p< 0.05), changes in the vascular pattern (OR = 3,748±0,477, p<0.05). Correlation analysis of the relationship between clinical (PUCAI), endoscopic (Rachmilewitz index) and laboratory markers of the inflammatory process (leukocytes, platelets, erythrocyte sedimentation rate, γ-globulins, fecal calprotectin, hemoglobin) has been also performed, the criteria of which might be used to monitor the course of the disease and the effectiveness of therapy.

show abstract

Laboratory values in Japanese children with newly diagnosed inflammatory bowel disease

Cited by 8 publications

References 15 publications

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

Features and Outcomes of Children with Ulcerative Colitis who Undergo a Diagnostic Change: A Single-Center Experience

Clinical Forms of Ulcerative Colitis and Their Features in Children

Contact Info

Product

Resources

About